한글목차

세계의 프롤로테라피 시장은 2024년에 12억 8,041만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 6.90%로 성장하여 19억 1,080만 달러에 이를 것으로 예측됩니다.

프롤로테라피(증식요법)는 주사를 기반으로 한 재생의료 치료로, 약화된 인대나 힘줄 부위에 조절된 염증 반응을 유도하여 신체의 자연 치유 과정을 자극하는 것을 목표로 합니다. 일반적으로 고삼투압 덱스트로스 용액을 사용하여 조직 재생을 촉진하고 결합 조직을 강화합니다. 세계 프롤로테라피 시장의 확대는 기본적으로 전 세계적으로 만성 근골격계 질환의 유병률 증가와 통증 관리를 위한 비수술적, 최소침습적 치료 대안에 대한 수요가 증가함에 따라 촉진되고 있습니다.

주요 시장 성장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 프롤로테라피 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(관절 주사 프롤로테라피, 인대 프롤로테라피, 건재건 프롤로테라피)
  • 용도별(병원, 외래 진료 센터, 정형외과 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 프롤로테라피 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 프롤로테라피 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 프롤로테라피 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 프롤로테라피 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 남아프리카공화국

제10장 남미의 프롤로테라피 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 프롤로테라피 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Pfizer Inc.
• Baxter International Inc.
• B. Braun AG
• Fresenius SE & Co. KGaA
• ICU Medical, Inc.
• Johnson & Johnson
• Arthex Inc.
• Aurobindo Pharma Limited
• Terumo Corporation
• Amphastar Pharmaceuticals, Inc.

제16장 전략적 제안

제17장 회사 소개 및 면책조항

영문목차

The Global Prolotherapy Market, valued at USD 1280.41 Million in 2024, is projected to experience a CAGR of 6.90% to reach USD 1910.80 Million by 2030. Prolotherapy, or proliferative therapy, is an injection-based regenerative medical treatment designed to stimulate the body's natural healing processes by inducing a controlled inflammatory response at the site of weakened ligaments and tendons, typically utilizing hyperosmolar dextrose solutions to foster tissue regeneration and strengthen connective tissues. The global prolotherapy market's expansion is fundamentally driven by the escalating prevalence of chronic musculoskeletal disorders worldwide and the growing demand for non-surgical, minimally invasive treatment alternatives for pain management.

Key Market Drivers

The escalating global prevalence of musculoskeletal disorders and chronic pain represents a primary market driver for prolotherapy. These conditions significantly impact quality of life and impose substantial healthcare burdens worldwide. The widespread nature of these ailments creates a consistently large patient pool seeking effective and less invasive treatment options. According to the International Association for the Study of Pain, in July 2023, "Global Burden of Musculoskeletal Conditions", an estimated 1.71 billion people globally were in need of rehabilitation due to musculoskeletal conditions, highlighting the extensive demand for therapies addressing such widespread issues. As incidence rates continue to rise, the foundational need for treatments like prolotherapy becomes increasingly pronounced, directly stimulating market expansion by providing solutions for persistent pain and functional limitations.

Key Market Challenges

The limited availability of robust, high-quality clinical evidence poses a significant impediment to the expansion of the global prolotherapy market. This evidentiary gap directly impacts the confidence of healthcare providers in recommending prolotherapy as a primary treatment option. Without comprehensive, long-term studies demonstrating consistent efficacy and safety, medical professionals often hesitate to integrate such interventions into standard practice protocols, thereby constraining patient referrals and limiting overall adoption rates.

Furthermore, the absence of strong clinical evidence fuels persistent regulatory uncertainty and contributes to variable insurance reimbursement policies across regions. For instance, according to the American Society of Interventional Pain Physicians (ASIPP) 2024 guidelines, the evidence for intradiscal injections of Platelet-Rich Plasma (PRP) and Mesenchymal Stem Cells (MSCs) is categorized as Level III, and Level IV for other related joint injections, on a five-level scale where Level I represents the strongest evidence. This limited strength of evidence for related regenerative therapies leads insurers to hesitate in covering treatments lacking substantial proof of long-term effectiveness. Such financial barriers reduce patient access, thereby stifling market penetration and growth.

Key Market Trends

Two key trends are significantly shaping the global prolotherapy market. Technological enhancements in injection guidance are improving the precision and safety of prolotherapy procedures, thereby increasing both practitioner confidence and patient acceptance. The integration of advanced imaging modalities, such as ultrasound, provides real-time visualization during injections, allowing for more accurate targeting of damaged tissues and minimizing potential complications. According to the Society of Diagnostic Medical Sonography, March 2024, "Now Available: Revised Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer," twenty participating organizations collaborated to revise the Scope of Practice and Clinical Standards for Diagnostic Medical Sonographers, reflecting the rapid technological advancements and evolving role of sonography in interventional procedures. This emphasis on enhanced guidance supports the widespread adoption of more accurate delivery methods for regenerative treatments.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• B. Braun AG
• Fresenius SE & Co. KGaA
• ICU Medical, Inc.
• Johnson & Johnson
• Arthex Inc.
• Aurobindo Pharma Limited
• Terumo Corporation
• Amphastar Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Prolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prolotherapy Market, By Type:

• Joint Injection Prolotherapy
• Ligament Prolotherapy
• Tendon Reconstruction Prolotherapy

Prolotherapy Market, By Application:

• Hospitals
• Ambulatory Care Centers
• Orthopedic Centers
• Others

Prolotherapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prolotherapy Market.

Available Customizations:

Global Prolotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prolotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Joint Injection Prolotherapy, Ligament Prolotherapy, Tendon Reconstruction Prolotherapy)
  • 5.2.2. By Application (Hospitals, Ambulatory Care Centers, Orthopedic Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Prolotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prolotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Prolotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Prolotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Prolotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prolotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Prolotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Prolotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Prolotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Prolotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Prolotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prolotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Prolotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Prolotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Prolotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Prolotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Prolotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prolotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Prolotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Prolotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Prolotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prolotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Prolotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Prolotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prolotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. B. Braun AG
• 15.4. Fresenius SE & Co. KGaA
• 15.5. ICU Medical, Inc.
• 15.6. Johnson & Johnson
• 15.7. Arthex Inc.
• 15.8. Aurobindo Pharma Limited
• 15.9. Terumo Corporation
• 15.10. Amphastar Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer